PHP Biotech was created to discover and develop an innovative approach to deal with solid cancers including, but probably not limited to, breast, lung, colorectal and pancreatic cancers, which are among the most diagnosed cancers worldwide. Current treatments have made progress against theses cancers, but not enough. With these unmet needs in mind, PHP Biotech research team has developed a pioneering compound (3-NAnTc) that is linked to a humanized single-domain antibody (sdAb) to enhance delivery and effectiveness in the fight against the most prevalent malignancies. Our technology allows multiple configurations of the sdAB, broadening the range of therapeutic possibilities and creating a platform of products to treat aggressive malignancies such as TNBC.

The molecule PHP Biotech developed has shown an ability to promote apoptosis while harnessing the development of metastatic disease allied with evidence of minimal toxicity. We envision 3-NAnTc being used as a monotherapy or as an add-on therapy against aggressive disease. Its favorable therapeutic ratio allows us to also consider its use in the maintenance setting so that  patients can continue with their productive life while fighting their disease.